Showing 1 - 7 results of 7 for search 'Mark R Middleton', query time: 0.47s
Refine Results
-
1
Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in a... by Elena Elez, Antonio Cubillo, Pilar Garcia Alfonso, Mark R. Middleton, Ian Chau, Baha Alkuzweny, Ann Alcasid, Xiaosong Zhang, Eric Van Cutsem
Published 2024-04-01
Article -
2
712 IMPORT-201 (IMP-MEL): a phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist (PORT-2) and pembrolizumab for advanced melanoma and non-small cell... by David Thompson, Mark R Middleton, David J Pinato, Ian Walters, Robert Krämer, Uzi Gileadi, Nicholas Coupe, Justin Fairchild, Russell Poe, Carri Browne, Steven Innaimo, Carmela De Santo
Published 2023-11-01Article -
3
PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non‐muscle‐invasive bladder cancer by Victoria K. Woodcock, Ji‐Li Chen, Karin Purshouse, Chrissie Butcher, Linda Collins, Caroline Haddon, Gillian Verrall, Leena Elhussein, Corran Roberts, Andrea Tarlton, Margarida Rei, Giorgio Napolitani, Mariolina Salio, Mark R. Middleton, Vincenzo Cerundolo, Jeremy Crew, Andrew S. Protheroe
Published 2023-05-01
Article -
4
Activated Regulatory T-Cells, Dysfunctional and Senescent T-Cells Hinder the Immunity in Pancreatic Cancer by Shivan Sivakumar, Enas Abu-Shah, David J. Ahern, Edward H. Arbe-Barnes, Ashwin K. Jainarayanan, Nagina Mangal, Srikanth Reddy, Aniko Rendek, Alistair Easton, Elke Kurz, Michael Silva, Zahir Soonawalla, Lara R. Heij, Rachael Bashford-Rogers, Mark R. Middleton, Michael L. Dustin
Published 2021-04-01
Article -
5
Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study by Jessica C Hassel, Mark R Middleton, Alexander N Shoushtari, Omid Hamid, Paolo A Ascierto, Todd M Bauer, John M Kirkwood, Friedegund Meier, Marlana Orloff, Paul C Lorigan, Chris Holland, Cornelia Mauch, Ramakrishna Edukulla, April K S Salama, Thomas R Jeffry Evans, Shaad E Abedin
Published 2023-06-01
Article -
6
The Circulating Transcriptome as a Source of Biomarkers for Melanoma by Carla Solé, Daniela Tramonti, Maike Schramm, Ibai Goicoechea, María Armesto, Luiza I. Hernandez, Lorea Manterola, Marta Fernandez-Mercado, Karmele Mujika, Anna Tuneu, Ane Jaka, Maitena Tellaetxe, Marc R. Friedländer, Xavier Estivill, Paolo Piazza, Pablo L. Ortiz-Romero, Mark R. Middleton, Charles H. Lawrie
Published 2019-01-01
Article -
7
705 Biodistribution and shedding analysis following RP1 oncolytic immunotherapy dosing in patients from the IGNYTE clinical trial by Dirk Schadendorf, Gino K In, Mark R Middleton, Mohammed Milhem, Adel Samson, Bartosz Chmielowski, Michael K Wong, Robert S Coffin, Trisha M Wise-Draper, Eva Muñoz-Couselo, Joseph J Sacco, Georgia M Beasley, Judith Michels, Praveen K Bommareddy, Katy K Tsai, Jeannie W Hou, Alina Monteagudo, Tawnya Lynn Bowles, Ari M VanderWalde, Jason Alan Chesney, Fade Mahmoud, Walter Hong, Aaron Clack
Published 2023-11-01Article